Literature DB >> 11992058

A comparison of multiple urine markers for interstitial cystitis.

Deborah R Erickson1, Sharon X Xie, Veer P Bhavanandan, Marcia A Wheeler, Robert E Hurst, Lawrence M Demers, Leslie Kushner, Susan K Keay.   

Abstract

PURPOSE: We measured several urine markers in 24-hour specimens from patients with interstitial cystitis and healthy controls. For each marker we determined whether the urine level was significantly different in interstitial cystitis and control cases, and whether the marker level correlated with the symptom score.
MATERIALS AND METHODS: Study participants included 36 female patients with interstitial cystitis and 36 age matched female volunteers. Multiple urine aliquots were obtained to measure the various markers.
RESULTS: Certain markers were significantly increased in interstitial cystitis, including anti-proliferative factor, epidermal growth factor, insulin-like growth factor (IGF) binding protein-3 and interleukin (IL)-6. Markers significantly decreased in interstitial cystitis were heparin-binding epidermal growth factor-like growth factor, cyclic guanosine monophosphate and methylhistamine. Other markers were not significantly different in the interstitial cystitis and control groups, including total glycosaminoglycans, epitectin, hyaluronic acid, IL-8, IL-1 and nitrates plus nitrites. IGF-1 was undetectable in 24-hour urine samples but spot voided samples from the same interstitial cystitis population had IGF-1 levels similar to previously reported levels. The only significant association of marker with symptom score was a positive correlation of IL-6 with nocturia. For all markers the conclusions were the same whether the marker was normalized to creatinine or to 24 hours.
CONCLUSIONS: This study confirmed several previously reported urine alterations in interstitial cystitis, including increased anti-proliferative factor, epidermal growth factor, IGF binding protein-3 and IL-6, and decreased heparin-binding epidermal growth factor-like growth factor and cyclic guanosine monophosphate. Of all markers studied anti-proliferative factor had the least overlap in the interstitial cystitis and control groups, and so it is the most likely candidate to become a diagnostic test.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992058

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  53 in total

1.  Role for pAKT in rat urinary bladder with cyclophosphamide (CYP)-induced cystitis.

Authors:  Lauren Arms; Margaret A Vizzard
Journal:  Am J Physiol Renal Physiol       Date:  2011-06-01

2.  Integration analysis of quantitative proteomics and transcriptomics data identifies potential targets of frizzled-8 protein-related antiproliferative factor in vivo.

Authors:  Wei Yang; Yongsoo Kim; Taek-Kyun Kim; Susan K Keay; Kwang Pyo Kim; Hanno Steen; Michael R Freeman; Daehee Hwang; Jayoung Kim
Journal:  BJU Int       Date:  2012-06-28       Impact factor: 5.588

3.  Changes in urine markers and symptoms after bladder distention for interstitial cystitis.

Authors:  Deborah R Erickson; Allen R Kunselman; Christina M Bentley; Kenneth M Peters; Eric S Rovner; Laurence M Demers; Marcia A Wheeler; Susan K Keay
Journal:  J Urol       Date:  2007-02       Impact factor: 7.450

4.  Assessing urgency in interstitial cystitis/painful bladder syndrome.

Authors:  Christina Diggs; Walter A Meyer; Patricia Langenberg; Patty Greenberg; Linda Horne; John W Warren
Journal:  Urology       Date:  2007-01-31       Impact factor: 2.649

5.  Urinary levels of glycosaminoglycans in patients with idiopathic detrusor overactivity.

Authors:  Salvatore Siracusano; Antonio Cucchi; Stefano Ciciliato; Nicolitza Lampropoulou; Franco Vittur
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-08-12

6.  Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens.

Authors:  Anthony T Corcoran; Naoki Yoshimura; Vikas Tyagi; Bruce Jacobs; Wendy Leng; Pradeep Tyagi
Journal:  World J Urol       Date:  2012-03-24       Impact factor: 4.226

7.  Is there a relation between urinary interleukin-6 levels and symptoms before and after intra-vesical glycosaminoglycan substitution therapy in patients with bladder pain syndrome/interstitial cystitis?

Authors:  Lukas K Daha; Dara Lazar; Reiner Simak; Heinz Pflüger
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-03-20

Review 8.  Bladder afferent hyperexcitability in bladder pain syndrome/interstitial cystitis.

Authors:  Naoki Yoshimura; Tomohiko Oguchi; Hitoshi Yokoyama; Yasuhito Funahashi; Satoru Yoshikawa; Yoshio Sugino; Naoki Kawamorita; Mahendra P Kashyap; Michael B Chancellor; Pradeep Tyagi; Teruyuki Ogawa
Journal:  Int J Urol       Date:  2014-04       Impact factor: 3.369

9.  Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder.

Authors:  Akira Furuta; Tokunori Yamamoto; Yasuyuki Suzuki; Momokazu Gotoh; Shin Egawa; Naoki Yoshimura
Journal:  Int Urogynecol J       Date:  2018-01-25       Impact factor: 2.894

10.  Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis/painful bladder syndrome.

Authors:  Deborah R Erickson; John E Tomaszewski; Allen R Kunselman; Christina M Stetter; Kenneth M Peters; Eric S Rovner; Laurence M Demers; Marcia A Wheeler; Susan K Keay
Journal:  J Urol       Date:  2008-03-18       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.